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Changes in Transcript, Metabolite, and Antibody 
Reactivity During the Early Protective Immune Response 
in Humans to Mycobacterium tuberculosis Infection
January Weiner,1 Teresa Domaszewska,1 Simon Donkor,2 Stefan H. E.  Kaufmann,1,3 Philip C. Hill,2,4 and Jayne S. Sutherland2
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Banjul, The Gambia; 3Hagler Institute for Advanced Study, Texas A&M University, College Station, USA; and 4Otago University, Otago, New Zealand
Background. Strategies to prevent Mycobacterium tuberculosis (Mtb) infection are urgently required. In this study, we aimed to 
identify correlates of protection against Mtb infection.
Methods. Two groups of Mtb-exposed contacts of tuberculosis (TB) patients were recruited and classified according to their 
Mtb infection status using the tuberculin skin test (TST; cohort 1) or QuantiFERON (QFT; cohort 2). A negative reading at baseline 
with a positive reading at follow-up classified TST or QFT converters and a negative reading at both time points classified TST or 
QFT nonconverters. Ribonucleic acid sequencing, Mtb proteome arrays, and metabolic profiling were performed.
Results. Several genes were found to be differentially expressed at baseline between converters and nonconverters. Gene set en-
richment analysis revealed a distinct B-cell gene signature in TST nonconverters compared to converters. When infection status was 
defined by QFT, enrichment of type I interferon was observed. A remarkable area under the curve (AUC) of 1.0 was observed for IgA 
reactivity to Rv0134 and an AUC of 0.98 for IgA reactivity to both Rv0629c and Rv2188c. IgG reactivity to Rv3223c resulted in an 
AUC of 0.96 and was markedly higher compared to TST nonconverters. We also identified several differences in metabolite profiles, 
including changes in biomarkers of inflammation, fatty acid metabolism, and bile acids. Pantothenate (vitamin B5) was significantly 
increased in TST nonconverters compared to converters at baseline (q = 0.0060).
Conclusions. These data provide new insights into the early protective response to Mtb infection and possible avenues to inter-
fere with Mtb infection, including vitamin B5 supplementation.
Keywords.  tuberculosis; immunology; RNA sequencing; mtb proteome arrays; mtb resisters.
It is estimated that more than 2 billion people are latently in-
fected with Mycobacterium tuberculosis (Mtb) worldwide, re-
sulting in 10 million new cases and 1.6 million deaths each year 
[1]. Strategies to prevent Mtb infection prior to establishment 
of latency are urgently needed. A recent study showed the rate 
of sustained QuantiFERON (QFT) conversion was reduced 
by 45.4% with a booster BCG vaccination of adolescents in a 
high-transmission setting [2]. Evidence for natural resistance to 
Mtb infection has been shown in some healthcare workers [3], 
South African miners [4], and sailors [5] who all were highly 
exposed but never showed signs of latent Mtb infection (LTBI). 
A  proportion of highly Mtb-exposed household contacts also 
shows no evidence of infection [6], and these individuals have 
a much lower rate of progression to tuberculosis (TB) disease 
than those with LTBI [7]. Recent studies from a Ugandan long-
term cohort of Mtb “resisters” showed evidence of higher im-
munoglobulin (Ig) M antibody reactivity in the resisters, which 
suggests that the definition of infection may not be accurate 
using interferon (IFN)-γ responses to Mtb antigens alone [8]. 
Another recent article from an Indonesian cohort looking at 
early infection conversions (within 14 weeks of exposure) found 
BCG vaccination provided some protection, which decreased 
with increasing exposure [9].
Several cell subsets have been proposed to be involved in 
resistance to Mtb infection, including both innate (ie, macro-
phages) and adaptive (ie, B or T cells) subsets [10]. Genome-
wide association analysis has also identified loci that are 
associated with innate or adaptive resistance to Mtb infection 
[11]. A recent study has shown that early clearance of Mtb is 
associated with enhanced heterologous (ie, trained) innate im-
mune responses [12].
Our aim in this study was to conduct an unbiased profiling 
of the global immune space in Mtb infection converters and 
nonconverters in The Gambia.
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METHODS
Study Participants
This study was nested within a larger study of household con-
tacts at Medical Research Council Unit The Gambia (MRCG). 
Household contacts of confirmed TB cases were consecutively 
recruited to this study within 2 weeks of diagnosis of the TB 
index case (Supplementary Figure 1). All participants were 
symptom screened to rule out active TB disease, and infec-
tion status was determined using either the tuberculin skin test 
(TST) or QFT (see the Supplementary Methods for details). 
Whole blood RNA was stabilized in Paxgene RNA blood tubes 
and stored at −80°C until analysis. Heparinized blood was cen-
trifuged (600gmax, 10 minutes), and the plasma collected and 
stored at −80oC until analysis.
RNA Sequencing
RNA was extracted using an RNeasy mini kit (Qiagen, Germany) 
according to the manufacturer’s instructions and shipped to the 
Beijing Genome Institute (Hong Kong) (see Supplementary 
Methods for further details).
IgG and IgA Mtb Proteome Arrays
IgG and IgA serum antibody reactivity to 4000 Mtb antigens 
was analyzed using a full proteome microarray by Antigen 
Discovery Inc. (USA) as previously described [13, 14] (see the 
Supplementary Methods for further details).
Metabolomic Profiling
Sample preparation was carried out as described previously [15] 
at Metabolon, Inc (see the Supplementary Methods for further 
details).
Statistical Analyses
See the Supplementary Methods for a detailed description of 
the analysis pipeline. Multiple testing was corrected using the 
Benjamini-Hochberg procedure for all analyses.
RESULTS
Participant Demographics
Analysis of TST at baseline and 3  months defined 2 partici-
pant groups: cohort 1, TST converters (those who were nega-
tive [0 mm] at baseline and converted to positive [>10 mm] by 
3 months) and TST nonconverters (ie, those who remained at 
0 mm at both time points; Supplementary Figure 1). Similarly, 
analysis of QFT at baseline and 6  months defined QFT con-
verters and nonconverters (cohort 2). An exposure score was de-
termined based on the smear grade of the index case (all index 
cases had a smear grade of 2 or above) and sleeping proximity 
of the contact to the index case (Supplementary Figure 1). For 
metabolic profiling and Mtb proteome arrays, paired plasma 
samples from 40 converters and 38 nonconverters (adults from 
cohort 1 only) at baseline and 3 months were sent to Metabolon 
and to Antigen Discovery for metabolomics and antibody ar-
rays, respectively. There was no significant difference in age or 
sex between the groups, but there was a significantly higher pro-
portion of converters living in the same room as the index case 
(ie, closest proximity; P  =  .0340) compared to nonconverters 
(Table 1). For RNA sequencing, 2 batches of analysis were per-
formed based on TST (cohort [batch] 1) or QFT (cohort [batch] 
2). For batch 1, 100 baseline RNA samples were sequenced. 
Quality control prior to library preparation revealed that only 
46/100 samples met the quality standards and were appropriate 
for sequencing (RNA Integrity Number [RIN]  ≥  7.0), pre-
sumably due to the long storage duration (up to 13 years). Of 
these 46 samples, 35 were TST nonconverters and 11 were TST 
converters (Table 1). There was a similar proportion of males 
in both groups, but a significant difference in age (median [in-
terquartile range] of nonconverters  =  10 [5–17] compared to 
20 [16–32] for the converters; P = .0005). There was no signifi-
cant difference in proximity or BCG vaccination status between 
the groups. For cohort 2, samples from 16 QFT nonconverters 
and 11 QFT converters were sequenced (Table 1). No signifi-
cant difference in age, sex, BCG vaccination status, or proximity 
was seen between the groups. Progression to active disease was 
assessed in all participants for a 24-month period with only 1 
QFT converter progressing after 12  months and none of the 
nonconverters progressing. No progressors were seen in the TST 
converter/nonconverter group.
Table 1. Participant Demographics
Demographic Nonconverters Converters P Value
Plasma n = 40 n = 38  
 Age, median (IQR) 22 (18–34) 26 (20–37) ns
 Male, n (%) 14 (35) 14 (37) ns
 Proximity, n (%)    
  Different house 15 (38) 10 (26) ns
  Different room 21 (53) 17 (45) ns
  Same room 4 (10) 11 (29) .0340
RNA tuberculin skin test n = 35 n = 11  
 Age, median (IQR) 10 (5–17) 20 (16–32) .0005
 Male, n (%) 18 (51) 5 (45) ns
 BCG vaccine, n (%) 15 (38) 4 (40) ns
 Proximity, n (%)    
  Different house 19 (54) 6 (55) ns
  Different room 14 (40) 5 (45) ns
  Same room 3 (9) 2 (18) ns
RNA QuantiFERON n = 16 n = 11  
 Age, median (IQR) 29 (19–47) 18 (17–34) ns
 Male, n (%) 8 (50) 4 (36) ns
 BCG vaccine, n (%) 9 (59) 8 (71) ns
 Proximity, n (%)    
  Different house 0 0 ns
  Different room 0 0 ns
  Same room 16 (100) 11 (100) ns
Abbreviations: BCG, Bacillus Calmette–Guérin; IQR, interquartile range; ns, not significant.
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RNA Sequencing
Several differentially expressed genes were observed between 
converters and nonconverters at baseline (Table 2). For the 
TST-defined group, the most differentially expressed genes in-
cluded TMEM56 (P  =  1.25E-08, q  <  10E-03), RP11-364L4.1 
(P = 4.52E-08, q < 10E-03), LCN2 (P = 1.81E-07, q < 10E-03), 
CLIC2 (P = 3.50E-07, q < 10E-02), and WASHC3 (P = 3.54E-
07, q < 10E-02; Table 2). For the QFT-defined group, the most 
differentially expressed genes included RPS9 (P  =  3.14E-
10), MDM4 (P  =  6.09E-07), HSFX3 (7.6E-07), and IGF1R 
(P = 5.25E-06), all of which were upregulated in the converters 
(Table 3, Supplementary Table 1). Due to the significant dif-
ference in age between the TST converters and nonconverters, 
we also performed filtered analysis of adults only (Table 4). 
Interestingly, the top genes in this group included several 
immune-regulatory genes such as CXCL10 (P  =  3.10E-05), 
HLA-DQB1 (P = 8.53E-04), and CD22 (P = 1.58E-03). However, 
significance was lost after adjusting for the false discovery rate 
(FDR), most likely due to low numbers in both groups. Next, 
we performed gene set enrichment analysis using the R-package 
tmod. In the total TST-defined group, there was a strong and 
statistically significant enrichment in B cell–related genes in 
the TST nonconverters (Figure 1A, left), which was still evi-
dent in the filtered subgroup (Figure 1A, right). TST converters 
had significant enrichment for TLR8-BAFF and monocyte-
related genes (Figure 1A), although this was lost when filtering 
was performed. The responses in the QFT nonconverters were 
dominated by IFN type I and antiviral gene signatures (LI.M75 
and LI.M127; Figure 1B). The enriched B cell–related modules 
included, among others, the genes BLK, CD19, CD22, CD24, 
CD72, CD79, CD200, CXCR5, CR2, and FCR1/2. The genes in 
the enriched IFN-related modules included TAP1, IFIH1, IRF7, 
Table 2. Differentially Expressed Genes in the Tuberculin Skin Test Group With a False Discovery Rate ≤0.01
Gene Log-fold Change P Value False Discovery Rate Description
TMEM56 2.29 1.25E-08 1.95E-04 Transmembrane protein 56; protein coding
RP11-364L4.1 2.83 4.52E-08 3.54E-04 Pseudogene
LCN2 2.42 1.81E-07 9.43E-04 Lipocalin 2; iron sequestering; innate immunity
CLIC2 1.22 3.50E-07 1.11E-03 Chloride intracellular channel; regulates cell processes
WASHC3 0.60 3.54E-07 1.11E-03 Endocytosis
AC010642.1 −1.50 8.25E-07 2.15E-03 Zinc finger protein pseudogene
CCDC153 1.43 1.25E-06 2.79E-03 Coiled-coil domain-containing protein 153
HNMT 1.28 1.60E-06 3.01E-03 Inactivates histamine by N-methylation
FAM114A1 1.59 1.73E-06 3.01E-03 Protein coding gene; neuronal cell development
MED20 0.92 2.03E-06 3.18E-03 Transcriptional coactivator complex
RAB10 0.80 3.17E-06 4.36E-03 Regulates intracellular vesicle trafficking
TCF4 −0.89 3.52E-06 4.36E-03 Transcription factor 4; extracellular signal regulated kinase signaling
CXCL9 2.39 3.62E-06 4.36E-03 T-cell trafficking; antimicrobial
SLC14A1 1.80 3.95E-06 4.42E-03 Mediates urea transport in erythrocytes
ATG3 0.67 4.56E-06 4.76E-03 Regulation of autophagy during cell death
ANAPC13 0.79 4.93E-06 4.82E-03 Class I major histocompatibility complex antigen processing and 
presentation 
TRIQK 0.75 5.89E-06 5.20E-03 Cell growth and maintenance of cell morphology
GLRX 1.10 5.98E-06 5.20E-03 Member of glutaredoxin family; antioxidant defense
NCOA4 0.98 8.41E-06 6.92E-03 Androgen receptor binding
BNIP3L 1.26 9.52E-06 7.45E-03 Pro-apoptotic subfamily within B-cell lymphoma-2 family of proteins
LINC00662 1.23 1.05E-05 7.68E-03 Noncoding RNA
DPCD 0.95 1.08E-05 7.68E-03 Possible role in the formation/function of ciliated cells
ARV1 1.09 1.15E-05 7.84E-03 Endoplasmic reticulum cholesterol and bile acid homeostasis
ARL6IP5 0.73 1.35E-05 8.27E-03 Regulates intracellular concentrations of taurine and glutamate; 
expression affected by vitamin A
FBXO9 0.78 1.37E-05 8.27E-03 F-box protein family; phosphorylation-dependent ubiquitination
DENND5B −1.24 1.37E-05 8.27E-03 Promotes the exchange of guanosine diphosphate to guanosine 
triphosphate
TBC1D27 −1.14 1.47E-05 8.37E-03 Pseudogene
OLFM4 3.14 1.50E-05 8.37E-03 Olfactomedin 4; antiapoptotic factor that promotes tumor growth
TMEM55A 1.02 1.57E-05 8.49E-03 Superpathway of inositol phosphate compounds
EVPL 1.42 1.81E-05 9.44E-03 Member of the plakin family of proteins; component of desmo-
somes and epidermal cornified envelope
IGFBP7 0.97 1.98E-05 9.79E-03 Member of the insulin-like growth factor–binding protein family
DCAF6 0.72 2.03E-05 9.79E-03 Ligand-dependent coactivator of nuclear receptors
FAM26F 1.32 2.07E-05 9.79E-03 Calcium homeostasis modulator family member 6
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Table 3. Differentially Expressed Genes in the QuantiFERON Group With a False Discovery Rate ≤0.05
Gene Log-fold Change P Value False Discovery Rate Description
RPS9 5.39 3.14E-10 4.87E-06 Ribosomal protein S9
MDM4 0.73 6.09E-07 3.97E-03 Mouse double minute 4 (MDM4), p53 reg-
ulator
HSFX3 6.04 7.66E-07 3.97E-03 Heat shock transcription factor family
RP60S −0.92 4.10E-06 1.59E-02 60S ribosomal protein pseudogene
IGF1R 0.72 5.25E-06 1.63E-02 Insulin-like growth factor 1 receptor
STRN3 0.80 9.23E-06 1.80E-02 Striatin 3; calmodulin binding protein
RPL39P3 −0.85 9.27E-06 1.80E-02 Ribosomal protein L39 pseudogene 3
PCNA −0.63 9.60E-06 1.80E-02 Proliferating cell nuclear antigen
PCK2 −0.62 1.18E-05 1.80E-02 Mitochondrial
POLR2L −0.63 1.26E-05 1.80E-02 RNA polymerase II subunit L
TFP1 5.47 1.31E-05 1.80E-02 Transferrin pseudogene 1
SYNE3 0.59 1.39E-05 1.80E-02 Actin binding
LAMTOR2 −0.68 1.71E-05 1.82E-02 Mitogen activated protein kinases and mam-
malian target of rapamycin activator 2
RNF181 −0.60 1.73E-05 1.82E-02 Ring finger protein 181
NKTR 0.73 1.82E-05 1.82E-02 Natural killer cell triggering receptor
PMVK −0.60 1.87E-05 1.82E-02 Phosphomevalonate kinase
C19orf70 −0.60 2.07E-05 1.89E-02 Chromosome 19 open reading frame 70
DPM3 −0.67 2.18E-05 1.89E-02 Dolichyl-phosphate mannosyltransferase 
HLA-DMA −6.98 2.51E-05 2.06E-02 MHC class II, DM alpha
HLA-B −6.14 2.90E-05 2.13E-02 MHC class I, B
HNRNPH1 0.65 2.96E-05 2.13E-02 Heterogeneous nuclear ribonucleoprotein H1
RARRES3 −0.67 3.02E-05 2.13E-02 Retinoic acid receptor responder 3
RBM25 0.58 4.35E-05 2.74E-02 RNA binding motif protein 25
LILRB3 −3.44 4.46E-05 2.74E-02 Leukocyte immunoglobulin like receptor B3
TMSB10 −0.59 4.54E-05 2.74E-02 Thymosin beta 10
STX16 0.48 4.61E-05 2.74E-02 Syntaxin 16
FBXO6 −0.80 4.77E-05 2.74E-02 F-box protein 6
MALAT1 0.69 5.26E-05 2.90E-02 Metastasis-associated lung adenocarcinoma 
0.87 5.47E-05 2.90E-02 Novel transcript, sense intronic to sup-
pressor of tumorigenicity
RPL29P11 2.33 5.60E-05 2.90E-02 Ribosomal protein L29 pseudogene 11
LMBR1L 0.47 6.41E-05 3.20E-02 Limb development membrane protein 1 like
TMEM170B 0.80 6.59E-05 3.20E-02 Transmembrane protein 170B
LTB 5.44 7.12E-05 3.35E-02 Lymphotoxin beta
PLEKHF1 −0.69 7.33E-05 3.35E-02 Triggers caspase-independent apoptosis
SERPING1 −1.76 7.85E-05 3.49E-02 Complement component 1 inhibitor
LINC01089 0.67 8.31E-05 3.59E-02 Long intergenic nonprotein coding RNA 1089
 0.96 9.11E-05 3.83E-02 Uncharacterized LOC100288123
SF3B1 0.49 9.67E-05 3.87E-02 Splicing factor 3b subunit 1
NDUFA4 −0.50 9.71E-05 3.87E-02 NDUFA4, mitochondrial complex associated
NKG7 −0.85 1.05E-04 4.01E-02 Natural killer cell granule protein 7
ULK1 0.53 1.06E-04 4.01E-02 unc-51 like autophagy activating kinase 1
SRSF11 0.57 1.15E-04 4.14E-02 Serine and arginine rich splicing factor 11
EPSTI1 −1.18 1.17E-04 4.14E-02 Epithelial stromal interaction 1
EIF4A1 0.98 1.17E-04 4.14E-02 Eukaryotic translation initiation factor 4A1
ATP11A 0.47 1.23E-04 4.24E-02 ATPase phospholipid transporting 11A
PSMG3 −0.57 1.52E-04 4.91E-02 Proteasome assembly chaperone 3
OAS1 −1.46 1.53E-04 4.91E-02 2’-5’-oligoadenylate synthetase 1
SERINC5 0.69 1.54E-04 4.91E-02 Serine incorporator 5
BANF1 −0.57 1.58E-04 4.91E-02 Barrier to autointegration factor 1
FOXK1 0.55 1.59E-04 4.91E-02 Forkhead box K1
AQR 0.67 1.61E-04 4.91E-02 Aquarius intron-binding spliceosomal factor
PAN3 0.45 1.66E-04 4.93E-02 Poly(A)-specific ribonuclease subunit PAN3
ECI1 −0.55 1.68E-04 4.93E-02 Enoyl-CoA delta isomerase 1
ZMYND15 1.10 1.73E-04 4.98E-02 Zinc finger myeloid, Nervy, and DEAF-1-type 
containing 15
Abbreviations; CoA, co-enzyme A; MHC, major histocompatibility complex.
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PARP9, STAT1, PLSCR1, IFITM1, HERC5, DDX60, USP18, 
RSAD2, and IFIT1. It is important to note that there were no 
significant differences in white blood cell counts between con-
verters and nonconverters (data not shown).
Given the differences in exposure of each participant to the 
index TB patient, we next assessed how this affected gene ex-
pression profiles (Figure 2). In the participants with the lowest 
exposure, the enriched gene modules were related to innate 
immune cells, including neutrophils, monocytes, and Toll-like 
receptor (TLR) pathways. The B-cell signature enrichment was 
only evident in those with the highest exposure to the index TB 
case (Figure 2).
Mtb Antibody Arrays
Analysis of both IgG and IgA reactivity to the Mtb proteome 
showed similar results, with extensive differences in reactivity 
evident (Supplementary Table 2). The most differential re-
sponses were seen in those with the highest exposure (proximity 
3). Analysis of IgG responses at baseline to Rv2131c, Rv0363c, 
and Rv3223c resulted in an area under the curve (AUC) of 0.73, 
0.83, and 0.96, respectively (Figure 3A). With IgA reactivity 
to Rv0134 at the closest proximity, the AUC was 1.00 (Figure 
3B). The reactivity was higher in the converters compared to 
the nonconverters at baseline (Figure 3A and 3B). At 3 months, 
differential responses were still evident with an AUC of 0.90 
seen for Rv1223-IgG levels and an AUC of 1.00 for Rv0037c-
IgA levels (both higher in the converters). IgG levels to Rv3541c 
were higher in the nonconverters compared to converters at 
3 months, with an AUC of 0.90. Interestingly, the only antigen 
to elicit a similar response at 3 months compared to baseline 
was Rv3596c-IgA, which was higher in the converters at both 
time points and gave an AUC of 0.93 at baseline and 0.95 at 
3 months.
We also analyzed antigens that gave the greatest reactivity (ie, 
highest antibody levels). For the nonconverters at baseline, the 
highest IgG responses were seen for Rv0831c (log-fold change [LFC], 
1.93), Rv3038c (LFC, 2.32), Rv2946c (LFC, 2.09), Rv3604c (LFC, 
2.53), Rv0726c (LFC, 1.93), and Rv2396 (LFC, 2.00; Figure 4A), 
whereas IgA responses were always lower in the TST nonconverters 
(Figure 4B). By 3 months, there were no significant differences be-
tween the 2 groups for either IgG or IgA responses (Figures 4C and 
4D), with high levels in both converters and nonconverters. IgG re-
sponses were all elevated in the nonconverters by 3 months (Figure 
4C), but the majority of IgA responses were increased in the con-
verters at both time points (Figure 4D).
Table 4. Differentially Expressed Genes in the Tuberculin Skin Test 
Group Aged ≥18 Years
Gene
Log-fold 
Change P Value
False Discovery 
Rate
CXCL10 3.97 3.10E-05 ns
MTRNR2L1 4.19 3.23E-05 ns
LILRB2 3.61 4.67E-04 ns
HNMT 1.40 4.89E-04 ns
EEF1A1P5 1.50 6.91E-04 ns
ADAMTS1 1.51 7.54E-04 ns
HLA-DQB1 −5.65 8.53E-04 ns
SRGAP3 −1.10 9.82E-04 ns
HOPX 0.85 1.12E-03 ns
CD22 −0.84 1.58E-03 ns
CLIC2 1.16 1.65E-03 ns
RP11-394B2.5 −0.85 1.70E-03 ns
FAM26F 1.60 1.71E-03 ns
CCDC114 −1.22 1.74E-03 ns
GSKIP 0.67 1.94E-03 ns
MRPS35 0.60 2.08E-03 ns
RP11-374P20.4 −1.44 2.19E-03 ns
LCN2 2.07 2.43E-03 ns
AC020951.1 −1.17 2.68E-03 ns
KIF19 −1.02 2.74E-03 ns
Abbreviation: ns, not significant.
Figure 1. Modular analysis of RNA sequencing data. A, Analysis of tuberculin 
skin test converters compared to nonconverters. Left column is unfiltered data, and 
right column is only participants aged ≥18 years. B, Analysis of QuantiFERON con-
verters compared to nonconverters (all aged ≥18 years). RNA sequencing data were 
analyzed using Tmod analysis (R-statistics). Depth of color indicates significance 
level, and width indicates effect size (area under the curve). Blue indicates higher 
in nonconverters, and red indicates higher in converters. Abbreviations: IFN, inter-
feron; NK, natural killer; QFT, QuantiFERON; TST, tuberculin skin test. 
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Next, we analyzed reactivity to ESAT-6, dominant secretory 
antigens from Mtb. Only individuals in the closest proximity 
to the index case showed any differential antibody reactivity to 
ESAT-6 antigens, with the most significant being IgG reactivity 
to Rv3875 (P = .0008). IgA reactivity to Rv3872 (P = .025) and 
Rv3871 (P = .030) were both increased in converters compared 
to nonconverters at baseline (Supplementary Table 2).
Metabolomic Profiling
TST converters showed a relative increase in inflammatory 
biochemicals at baseline compared to nonconverters such as 
9-HETE (q =  0.0005; Figure 5A). Primary bile acids such as 
glycochenodeoxycholate sulfate and taurocholenate were also in-
creased in TST converters at baseline (q = 0.0024 for both; Figure 
5B [taurocholenate shown]). Kynurenine was elevated in con-
verters compared to nonconverters at 3 months, but differences 
were not significant after correcting for FDR (Supplementary 
Table 3). In nonconverters, increases were observed for pimelate, 
suberate, azelate, and undecanedioate at 3  months compared 
to baseline, with trends toward an increase in dodecanedioate 
and eicosanodioate, consistent with changes in omega-
oxidation. Significantly higher levels in biochemicals related 
to beta-oxidation (eg, medium-chain or long-chain fatty acids, 
acylcarnitines, and the ketone body 3-hydroxybutyrate) and in 
arginine and homoarginine were seen in converters compared 
to nonconverters at both baseline and 3 months (Supplementary 
Table 3). There was also a significantly lower relative abun-
dance in alpha-ketoglutarate and a higher relative abundance in 
homocitrulline in converters compared to nonconverters at base-
line only (Supplementary Table 3). One of the few metabolites 
that was higher in TST nonconverters compared to converters 
was pantothenate (vitamin B5), with a normalized median (inter-
quartile range) of 1.03 (0.81–1.22) compared to 0.87 (0.78–0.99) 
for the converters (q = 0.0060; Figure 5C).
DISCUSSION
We characterized host transcriptomic, metabolomic, and 
antibody responses to Mtb in TST nonconverters and con-
verters prior to any signs of infection as determined by current 
Figure 2. Exposure level influences gene expression profiles. A, Analysis of tuberculin skin test (TST) converters vs nonconverters with low exposure. B, Analysis of TST 
converters vs nonconverters with high exposure. Exposure was defined based on smear grade of the index case and sleeping proximity of the contact to the index case. Only 
the high-exposure group showed the B-cell signature seen when all samples were analyzed (rectangles). Depth of color indicates significance level, and size indicates effect. 
Abbreviations: ATF,  activating transcription factor; C-MYC, c-Master Regulator of Cell Cycle Entry and Proliferative Metabolism; TLR, Toll-like receptor.
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methods. We have previously shown higher levels of soluble in-
terleukin (IL)-17 in nonconverters at baseline [21], suggesting 
they have encountered Mtb and mounted an immune response 
and are not simply anergic to antigens in the current tests and 
that Mtb was not blocked by physiological barriers. In this study, 
we identified a distinct antigen-specific antibody signature re-
flected by differential antibody responses in TST converters and 
nonconverters to multiple Mtb antigens. Intriguingly, defining 
infection based on QFT rather than TST revealed a distinct type 
I IFN/antiviral gene signature.
Analysis of RNA from TST converters and nonconverters at 
baseline highlighted several differentially expressed genes. These 
included CXCL9 and BNIP3L, which were both upregulated 
in converters. CXCL9 is a T-cell chemoattractant induced by 
IFN-γ, which has been shown to exacerbate pathology in se-
vere TB disease [22]. BNIP3L (BCL2 interacting protein 3 like) 
is a proapoptotic protein whose substrate is PARK2, which in 
turn is important for the ubiquitination and clearance of Mtb 
[23]. We also observed upregulation of SLC14A1, which is in-
volved in urea transport, and of LCN2, which is involved in iron 
Figure 3. Differential antibody responses to the Mycobacterium tuberculosis (Mtb) proteome. Analysis of IgG (A and C) and IgA (B and D) antibody responses to Mtb 
antigens at baseline (A and B) and 3  months (C and D). The most differentially expressed antibodies are shown. Red indicates the group with the highest response. 
Abbreviations: AUC, area under the curve; C, converters; Ig, immunoglobulin; NC, nonconverters. 
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sequestration and innate immunity in converters prior to con-
version. Polymorphisms in SLC14A1 have been shown to be 
associated with susceptibility to TB [24], while LCN2 (lipocalin 
2) has been shown to confer a growth advantage on Mtb in the 
early stages of infection by supplying a source of iron to Mtb in 
infected macrophages [25]. When modular analysis was per-
formed, we observed a significant enrichment of B-cell genes in 
TST nonconverters compared to converters, while converters had 
enrichment of monocyte genes and TLR8-BAFF, which is impor-
tant in the early airway epithelial response to Mtb [26]. The B-cell 
genes of interest included CD72, which is thought to mediate 
B cell–T cell interaction, and CD19, CD22, CD24, and CD200, 
which are all phenotypic/maturation markers. High-affinity FCR 
genes are enriched in active TB compared to latent TB [27] and 
Figure 4. Mycobacterium tuberculosis (Mtb) antigens with the highest reactivity. Analysis of IgG (A and C) and IgA (B and D) antibody responses to Mtb antigens at baseline 
(A and B) and 3 months (C and D). The antibodies showing the highest responses are shown. Red indicates the group with the highest response. Abbreviations: AUC, area 
under the curve; C, converters; Ig, immunoglobulin; NA, not applicable; NC, nonconverters. 
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were recently shown to comprise prognostic markers of progres-
sion to active TB in Gambian household contacts [28].
Interestingly, different gene signatures were identified 
when QFT was used to diagnose infection status. While dif-
ferent mechanisms will be inevitable since TST is based on a 
delayed-type hypersensitivity reaction of 48–72 hours and QFT 
is based on overnight in vitro antigen stimulation of T cells, 
the upregulation of these signatures in the uninfected groups 
shows that they are likely to play a role in resistance of Mtb. 
Increased production of type I IFNs (IFN-α/-β) as part of the 
antiviral response inhibits the downstream effects of type II IFN 
(IFN-γ) responses known to be critical for Mtb control [29]. 
Thus, the increase in these genes in the QFT nonconverters 
was surprising. However, evidence has been presented that 
in the absence of a response to IFN-γ, type I  IFN can play a 
nonredundant protective role against TB in mice [30] and is re-
quired for the production of IL-12 and tumor necrosis factor in 
humans [31]. This suggests that low abundance of type I IFNs 
may be protective in the context of a low burden of Mtb. It has 
also been shown in experimental models that type I IFN may 
play a protective role in the context of BCG-induced immunity 
and could be targeted to improve preventive vaccination against 
TB [32, 33]. B cells have gained recognition recently, with sev-
eral studies highlighting the immunoregulatory role of B cells in 
controlling Mtb infections, which extends beyond their direct 
antibody- mediated effector functions [34, 35]. Furthermore, 
a previous study showed preferential IgA VH3‐23, D3‐3, JH4 
gene usage in TST-negative nurses with high and repeated ex-
posure to Mtb [36]. B cells have also been shown to be a source 
of type I IFN [37]. Thus, it is possible that the differences seen in 
our TST- and QFT-defined signatures (ie, B cells vs type I IFN) 
are actually reflecting related immunologic pathways to protect 
against early Mtb infection.
Because the enrichment of B-cell genes was unexpected, we 
analyzed IgG and IgA plasma antibody reactivity to all 4000 
Mtb proteins from these individuals. TST converters had signif-
icantly higher levels of both IgG and IgA antibodies to multiple 
Mtb antigens at baseline, which allowed excellent discrimi-
nation between converters and nonconverters. This was par-
ticularly evident when proximity was accounted for; exposed 
contacts in closest proximity to the index case who later con-
verted their TST had higher antibody levels at baseline, with 
levels increasing for both converters and nonconverters by 
3  months. While this may relate to the length of exposure, 
which is difficult to ascertain in this cohort, our data suggest 
that antibodies are playing a role in the response to Mtb infec-
tion but are not necessarily protecting the host from becoming 
infected (although a few antigens elicited significantly higher 
IgG responses in the nonconverters). Since we identified a dis-
tinct B-cell signature in the nonconverters, we conclude that 
other antibody-independent functions of B cells are driving 
protection against Mtb infection, and this is currently being as-
sessed in our laboratory.
We observed several differences in the relative abundances 
of circulating plasma metabolites, including changes in bio-
markers of inflammation, fatty acid metabolism, and bile acids. 
Increases in inflammation-related metabolites in converters 
could indicate increased immune activation, with 1 previous 
Figure 5. Metabolomic profiling of tuberculin skin test (TST) converters 
and nonconverters. Metabolite analysis of plasma from TST converters and 
nonconverters was performed. At baseline, increases in (A) 9-HETE and (B) 
taurocholenate levels in converters was seen. (C) Pantothenate levels were in-
creased in nonconverters at baseline. Data were analyzed using the Mann–Whitney 
U test. Line indicates median.
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study correlating IL-1β secretion with increased susceptibility 
to infection [38]. Interestingly, 1 of the only metabolites to be 
at statistically higher abundance in nonconverters compared 
to converters was pantothenate (vitamin B5). Vitamin B5 has 
recently been shown to significantly inhibit the growth of Mtb 
in mice by regulating innate immunity and adaptive immunity 
[39]. Together with our findings, this suggests that vitamin B5 
could be harnessed for host-directed intervention to enhance 
management of TB.
A recent study from Uganda has shown an enhanced an-
tibody reactivity to Mtb antigens in long-term Mtb resisters 
[8]. In addition, exposed but uninfected Chinese health-
care workers have been shown to have circulating protective 
antibodies [3], suggesting that these individuals have en-
countered antigen and have since cleared it. This supports 
the findings in our study and in another recent study from 
Indonesia [9] that show that enhanced antibody reactivities 
persist to clear the pathogen. The INFECT study in Indonesia 
also showed 45% protection from primary infection by BCG 
in the early clearer group [9], while we observed no influ-
ence of BCG. The level of protection by BCG in INFECT was 
strongest in those with low exposure, which may explain this 
difference.
In conclusion, despite being clinically healthy and showing 
no signs of latent infection by canonical diagnostic tests, we 
were able to demonstrate differential immune responses in pa-
tients who would later convert to a positive TST compared to 
those who remained TST negative. A potential shortcoming of 
our study is the relatively small number of evaluated partici-
pants and the unbalanced design (especially in the TST group), 
which may have had a negative impact on the robustness of our 
findings. An independent future validation of our study is nec-
essary to confirm our predictions.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases on-
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